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Oxidative stress plays a major role in metabolic disorders and
a wide range of chronic diseases such as diabetes mellitus,
obesity, metabolic syndrome, aging, cancer, osteoporosis,
rheumatoid arthritis, cardiovascular diseases, and neurode-
generative disorders. In addition, drug-induced organ injury
is well known to be associated with oxidative stress and
inflammation. Considerable evidence indicates that oxidative
stress and inflammation are the key pathophysiological pro-
cesses underpinning these disorders. Therefore, modulation
of oxidative stress represents an important strategy for the
treatment of multiple human diseases.
The transcription factor nuclear factor erythroid 2 related
factor 2 (Nrf2) is the master regulator of the basal and induc-
ible expression of a large network of cytoprotective and anti-
oxidant genes [1]. Under basal conditions, Nrf2 is bound to
Kelch-like ECH-associated protein 1 (Keap1) which functions
as a sensor protein against electrophiles and reactive oxygen
species (ROS). Upon cell stimulation, Nrf2 dissociates from
Keap1 and activated Nrf2 is translocated into the nucleus
where it binds to the antioxidant response element (ARE)
and leads to expression of target genes including heme oxy-
genase-1, NAD(P)H:quinone oxidoreductase 1, superoxide
dismutase, catalase, glutathione peroxidase, and glutathione-
S-transferase [2]. Thus, Nrf2 plays a role as a multiorgan pro-
tector against oxidative stress via inducing target genes. In
recent years, Nrf2 has shown promise as a novel therapeutic
target in diseases with underlying oxidative and inflammatory
stress components [3–6].
Peroxisome proliferator-activated receptors (PPARs) are
proteins that belong to the nuclear receptor family of
ligand-activated transcription factors. The three main forms
of peroxisome proliferator-activated receptors (PPARα,
PPARβ/δ, and PPARγ) belong to a superfamily of nuclear
receptors that function as transcription factors regulating
the expression of multiple genes. Upon ligand binding, they
form heterodimers with retinoid X receptor (RXR) and result
in modulation of gene transcription [7]. PPARs regulate a
variety of biological processes in various tissues. Among their
effects, PPARα controls lipid metabolism and inflammatory
processes [8], PPARβ/δ regulates glucose utilization, cell
differentiation, and inflammation [9], and PPARγ is involved
in adipocyte differentiation, glucose metabolism, and inflam-
matory pathways [10]. Upon activation, PPARs are known to
exert anti-inflammatory and antioxidant properties via
suppressing nuclear factor-κB, decreasing ROS production,
and upregulating the expression of antioxidant enzymes [11].
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Recent reports point to coactivation and possible
interaction between PPARs and Nrf2 through multiple
mechanisms. Coactivation of PPARγ and Nrf2 has been
shown to protect against oxidative stress, inflammation,
and carcinogenesis [4, 5, 12–14]. Ongoing and future
research will probably provide efficient PPARs and Nrf2
modulating agents for preventing and treating metabolic
and other common disorders.
This special issue encompasses cutting edge research and
review articles focusing on the role of Nrf2 and PPARs in
modulating oxidative stress and inflammation. It includes 8
novel research articles and 3 reviews describing the role of
Nrf2 and PPARs in various pathological conditions, summa-
rized as follows:
(1) Drug-induced oxidative stress and hepatotoxicity
Research article: “Gamma-Glutamylcysteine Ethyl Ester
Protects against Cyclophosphamide-Induced Liver Injury
and Hematologic Alterations via Upregulation of PPARγ
and Attenuation of Oxidative Stress, Inflammation, and
Apoptosis.” In this article, S. Alqahtani and A. M. Mahmoud
introduced evidence demonstrating the involvement of
PPARγ in mediating the hepatoprotective effect of the syn-
thetic glutathione precursor gamma-glutamylcysteine ethyl
ester. Activation of PPARγ resulted in enhancement of
antioxidant defenses and attenuation of cyclophosphamide-
induced oxidative stress, inflammation, and apoptosis.
Review article: “Collaborative Power of Nrf2 and
PPARγ Activators against Metabolic and Drug-Induced
Oxidative Injury.” C. Lee reviewed the general features
of PPARγ and Nrf2 signaling pathways in the context
of oxidative stress conditions. One of the main sections
of this review was the role of natural and synthetic
Nrf2 and PPARγ activators and the crosstalk between Nrf2
and PPARγ in alleviating drug-related oxidative stress
and damage.
(2) Endocrine system and diabetes
Research article: “NRF2 Plays a Critical Role in Both
Self and EGCG Protection against Diabetic Testicular
Damage.” This study by C. Pan et al. aimed to evaluate
the protective role of epigallocatechin gallate (EGCG)
against diabetic testicular damage and addressed the
requirement of Nrf2. Eight-week-old normal and diabetic
male C57BL/6 wild-type and Nrf2 knockout mice were
treated with EGCG for 24 weeks. Nrf2 knockout abrogated
both self and EGCG protection against diabetes-induced
testicular weight loss, reduction in spermatozoa count,
apoptotic cell death, endoplasmic reticulum (ER) stress,
inflammation, and oxidative damage. Therefore, this study
provides evidence that Nrf2 plays a central role in mediat-
ing the protective effect of EGCG against diabetic-induced
testicular damage.
Research article: “Activation of the Nrf2-Keap 1
Pathway in Short-Term Iodide Excess in Thyroid in Rats.”
The effect of normal and high iodide intake on the antiox-
idative action of sulfredoxin (Srx) and peroxiredoxin 3
(Prx 3) via Nrf2-Keap 1 pathway has been investigated
in the thyroid of rats. The expression of Srx and Prx 3
are known to be regulated via Nrf2. Srx is a member of
the oxidoreductase family that contributes to cellular redox
balance, and Prx 3 is a critical scavenger for mitochon-
drial ROS. The results showed that the activation of
Nrf2 signaling, Srx, and Prx 3 may play a key role in pro-
tecting the thyroid gland from excess iodide-induced
oxidative stress.
Research article: “Antioxidant Treatment Induces Hyper-
activation of the HPA Axis by Upregulating ACTH Receptor
in the Adrenal and Downregulating Glucocorticoid Recep-
tors in the Pituitary.” J. P. Prevatto et al. tested the hypothesis
that an imbalance in the redox system not only increases ROS
production but also alters the homeostasis of the
hypothalamus-pituitary-adrenal (HPA) axis culminating in
its hyperactivation. The results showed activated HPA axis,
increased levels of systemic glucocorticoids, decreased
expression of Nrf2 and HO-1 in the pituitary, upregulated
adrenocorticotropic hormone (ACTH) receptors in the adre-
nal gland, and downregulated glucocorticoid receptors in the
pituitary. Therefore, the indiscriminate use of antioxidants
may represent a risk to develop several morbidities related
to persistent hypercorticoidism.
(3) Nonalcoholic steatohepatitis
Research article: “Genetic Nrf2 Overactivation Inhibits
the Deleterious Effects Induced by Hepatocyte-Specific c-
met Deletion during the Progression of NASH.” Based
on the previous findings that overexpression of Nrf2 was
able to reduce triglyceride accumulation and ROS produc-
tion and suppress the levels of liver steatosis and fibrosis
in c-met-deficient hepatocytes, P. Ramadori et al. provided
in vivo evidence for the role of Nrf2 in preventing the
deleterious effects induced by hepatocyte-specific c-met
deletion during the progression of nonalcoholic steatohe-
patitis (NASH). In c-met/Keap1 knockout mice fed a
methionine-choline-deficient (MCD) diet, Nrf2 overex-
pression reduced triglycerides accumulation, dampened
the exacerbation of oxidative stress, drastically reduced
the number of apoptotic cells, decreased the influx of infil-
trating inflammatory cells, and attenuated the enhanced
development of fibrosis.
(4) Hepatic encephalopathy
Research article: “Commiphora molmol Modulates
Glutamate-Nitric Oxide-cGMP and Nrf2/ARE/HO-1 Path-
ways and Attenuates Oxidative Stress and Hematological
Alterations in Hyperammonemic Rats.” In a rat model of
hyperammonemia, a serious complication of liver disease
whichmay lead to encephalopathy and death, A.M.Mahmoud
et al. investigated the effect of Commiphora molmol resin
extract on the glutamate-NO-cGMP and Nrf2/ARE/HO-1
signaling pathways. Activation of Nrf2 by C. molmol resin
extract protected against excess ammonia via attenuation
of oxidative stress and inflammation and modulation of
the glutamate-NO-cGMP signaling pathway. In addition,
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C. molmol prevented hematological alterations and amelio-
rated both the activity and the expression of cerebral
Na+/K+-ATPase and therefore might be a promising protec-
tive agent against hyperammonemia.
(5) Chronic kidney disease
Research article: “Expression of the NRF2 Target Gene
NQO1 Is Enhanced inMononuclear Cells in Human Chronic
Kidney Disease.” Reduced Nrf2 activity has been reported in
models of chronic kidney disease (CKD). In this study, J.
Shen et al. quantified the NQO1 gene expression as a readout
parameter for Nrf2 signaling in monocytes of patients with
CKD with and without dialysis therapy. When compared to
healthy control subjects, CKD patients showed an upregu-
lated gene expression of Nrf2 and NQO1 and a slight increase
in the NQO1 protein content in monocytes from these
patients. The study concluded that Nrf2 activation in mono-
cytes of CKD patients is modulated through an influence on
both gene expression and protein content of Nrf2 targets in a
complex way.
(6) Cardiovascular function and disease
Review article: “The Role of Nrf2 in Cardiovascular
Function and Disease.” In this review article, S. Satta et al.
summarized the mechanisms regulating the activity of
Nrf2 and the role of Nrf2 in preventing mitochondrial dys-
function in cardiovascular disease. The authors highlight
the central role of Nrf2 signaling in endothelial dysfunction,
atherosclerosis, vascular calcification, hypertension, diabetic
cardiomyopathy, and in the aging heart. In the last section
of this review, the authors provide a summary of the role of
Nrf2 activators in the treatment of cardiovascular disease.
Research article: “Probucol Protects Rats from Cardiac
Dysfunction Induced by Oxidative Stress Following Cardio-
pulmonary Resuscitation.” The objective of this study was
to investigate the protective effect of the lipid-lowering agent
probucol on cardiac injury induced by cardiac arrest (CA) in
rats. CA is one of the most critical cardiovascular phenom-
ena. Probucol protected against CA in rats as evidenced by
the improved restoration of spontaneous circulation (ROSC)
rate, alleviated oxidative stress, prolonged survival time, and
improved hemodynamic parameters, and cardiac function.
These protective effects of probucol are mediated through
activating Nrf2 signaling.
(7) Pregnancy disorders
Review article: “Modulatory Mechanism of Polyphenols
and Nrf2 Signaling Pathway in LPS Challenged Pregnancy
Disorders.” In this review article, T. Hussain et al. focused
on the modulatory activity of flavonoids on oxidative
stress-mediated pregnancy insults. They describe the role of
Nrf2 activation in cases of pregnancy disorders.
The editors anticipate this special issue to be of inter-
est to the readers and expect researchers to benefit in
making further progress in the understanding of Nrf2 and
PPARs activators.
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